New preclinical research indicates the protein CCN5 can significantly reduce cardiac cellular senescence, a state where cells stop dividing and promote inflammation, potentially offering a new therapeutic strategy for cardiovascular diseases (CVD).
Scientists investigated if CCN5, known for its anti-fibrotic effects, could directly impact cardiac cellular senescence. Experiments using established markers like p53, p21, and DNA damage indicators showed CCN5 inhibited senescence induced by doxorubicin, a drug known to cause heart damage. Crucially, CCN5 also disrupted the senescence-associated secretory phenotype (SASP), a harmful inflammatory signaling cascade that senescent cells use to affect surrounding tissue. This suggests CCN5 acts both within individual cells and to mitigate damaging intercellular communication.
Furthermore, CCN5 helped restore the natural cell death process in senescent cells, aiding in the removal of damaged tissue. In a mouse model of heart attack, CCN5 treatment reduced senescence, validating its relevance in living organisms. While further human studies are needed, CCN5 shows potential as a dual therapy for fibrosis and senescence, which could slow structural and functional decline in heart disease.